Intra-Cellular Therapies (STU:23I) Growth Rank : 0 (As of Jun. 09, 2024)

View and export this data going back to 2015. Start your Free Trial

What is Intra-Cellular Therapies Growth Rank?

Intra-Cellular Therapies has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Intra-Cellular Therapies Growth Rank Related Terms

Thank you for viewing the detailed overview of Intra-Cellular Therapies's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Intra-Cellular Therapies (STU:23I) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Intra-Cellular Therapies Inc (STU:23I) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

ITCI:USA ITCI:Mexico 23I:Germany

Address

430 East 29th Street, New York, NY, USA, 10016

Website

https://www.intracellulartherapies.com

Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.

Intra-Cellular Therapies (STU:23I) Headlines

No Headlines